Karolinska Development: Modus granted IND
Research Note
2018-11-07
10:52
Karolinska Development announced today that Modus Therapeutics has been granted Investigational New Drug (IND) status, paving the way for a phase I trial with a subcutaneous formulation of Sevuparin in the U.S. The announcement was in line with our expectations and will not affect our valuation of Karolinska Development.
AN
AH
Arvid Necander
Anders Hedlund
Disclosures and disclaimers